Zobrazeno 61 - 70
of 86
pro vyhledávání: '"Maria R. Parkhurst"'
Autor:
Maria R. Parkhurst, Yong Li, Steven A. Rosenberg, John P. Riley, Mona El-Gamil, Panida Tong-On, Paul F. Robbins
Publikováno v:
The Journal of Immunology. 168:2402-2407
Multiple human cancer Ags have been identified, although little is known concerning which would be most effectively used in cancer immunotherapy. To gain insight into the selection of appropriate Ags, the immunologic reactivity of a patient who had a
Autor:
Steven A. Rosenberg, Simon Turcotte, Maria R. Parkhurst, Paul F. Robbins, John R. Wunderlich, Robert Somerville, Alena Gros, Yong-Chen Lu, Katherine Hogan, Eric Tran, James Chih-Hsin Yang, Mark E. Dudley, Christian S. Hinrichs
Publikováno v:
Science (New York, N.Y.). 344(6184)
T Cells for Epithelial Tumors Malignant tumors harbor genetic alterations. Recently, adoptive T cell therapies have taken advantage of this: T cells specific for mutations in tumors are infused into patients to generate an antitumor immune response.
Autor:
Rosati Shannon Faith, Paul F. Robbins, Zhili Zheng, Hui Xu, Maria R. Parkhurst, Mary A. Black, David A. Schrump, Rachel E. Beard, Young Hong, Steven A. Feldman, Daniel Abate-Daga, Richard A. Morgan, Steven A. Rosenberg, Mahadev Rao
Publikováno v:
J Immunother
Cancer testis antigens, such as NY-ESO-1, are expressed in a variety of prevalent tumors and represent potential targets for T-cell receptor (TCR) gene therapy. DNA encoding a murine anti-NY-ESO-1 TCR gene (mTCR) was isolated from immunized HLA-A*020
Publikováno v:
Journal of Immunotherapy. 24:212-220
Tyrosinase has many advantages as a target antigen for the immunotherapy of patients with melanoma because it is expressed in nearly all melanoma specimens with a high degree of cellular homogeneity, and its distribution in normal tissues is limited
Publikováno v:
Journal of Immunotherapy. 24:1-9
NY-ESO-1 is an attractive candidate tumor antigen for the development of immunotherapy for a wide variety of cancers. It is expressed in multiple types of tumors, but its normal tissue distribution is predominantly limited to the testes and ovaries;
Autor:
Yutaka Kawakami, Paul F. Robbins, Xiang Wang, Janis P. Tupesis, Maria R. Parkhurst, Xiaoqiang Kang, Kazuyasu Sakaguchi, Ettore Appella, Steven A. Rosenberg
Publikováno v:
The Journal of Immunology. 161:6985-6992
To isolate melanoma Ags recognized by T cells, cDNA libraries made from melanoma cell lines were screened with four CTLs derived from tumor infiltrating lymphocytes (TIL) that were able to recognize melanoma cells in a HLA-A1, -A2, or -A3 restricted
Autor:
Willem W. Overwijk, Kangla Tsung, Maria R. Parkhurst, Steven A. Rosenberg, Nicholas P. Restifo, Chunlei Liu, Miles W. Carroll, Theresa J. Goletz, Allan Tsung, Bernard Moss, Kari R. Irvine
Publikováno v:
The Journal of Experimental Medicine
Many tumor-associated antigens are nonmutated, poorly immunogenic tissue differentiation antigens. Their weak immunogenicity may be due to “self”-tolerance. To induce autoreactive T cells, we studied immune responses to gp100/pmel 17, an antigen
Autor:
Francesco M. Marincola, Maria R. Parkhurst, Susan L. Schwarz, Suzanne L. Topalian, Claudia A. Seipp, John R. Wunderlich, James Chih-Hsin Yang, Yutaka Kawakami, Paul J. Spiess, Nicholas P. Restifo, Mark E. Dudley, Patrick Hwu, Donald E. White, Steven A. Rosenberg, Jan Einhorn, Douglas J. Schwartzentruber
Publikováno v:
Nature Medicine. 4:321-327
The cloning of the genes encoding cancer antigens has opened new possibilities for the treatment of patients with cancer. In this study, immunodominant peptides from the gp100 melanoma-associated antigen were identified, and a synthetic peptide, desi
Autor:
Maria R. Parkhurst, W. Mark Saltzman
Publikováno v:
Journal of Controlled Release. 42:273-288
The interaction between infected leukocytes and mucosal epithelia is likely to play a critical role in the sexual transmission of certain diseases. It may be possible to prevent the transmission of intracellular pathogens by inhibiting leukocyte-epit
Publikováno v:
The Journal of Experimental Medicine
Tumor infiltrating lymphocytes (TILs) derived from tumor-bearing patients recognize tumor-associated antigens presented by major histocompatibility complex (MHC) class I molecules. The infusion of TIL586 along with interleukin (IL) 2 into an autologo